Page 35 - Merck Sharp News Today

This open-label randomized trial compares the effect of remdesivir (5 or 10 days) vs standard care on clinical status 11 days after treatment initiation among p

/PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world,...

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning among key areas of investment for pharma LONDON, May 17, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a

Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002... | May 17, 2023

Potent antivirals to combat some of the most serious diseases facing humanity May 2023 Nasdaq: COCP... | May 17, 2023

The psychosis in Parkinson's and Alzheimer's disease market size shall grow during the forecast period (2023-2032). This increase will be due to rising disease awareness and improving diagnosis

/PRNewswire/ -- DelveInsights Psychosis in Parkinsons and Alzheimers Disease Market Insights report includes a comprehensive understanding of current...

Monica Bertagnolli, Biden's nominee for Director of the National Institutes of Health (NIH), got nearly $300 million in grants from pharmaceutical companies.

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 -- Vaccinex,... | May 15, 2023

Recent Australian decisions have resulted in both new opportunities to challenge patent term extensions in Australia and new patent prosecution practices to shield against them. We summarise here what is known about PTE, and the areas that are ripe for further challenge.